Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
In: A Phase 1, Single Arm, Single Center Pilot Study of Medi4736, an Anti-Pdl1 Therapy, for Patients With Myelofibrosis
Online
report
Titel: |
Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
|
---|---|
Autor/in / Beteiligte Person: | Celgene ; The Leukemia and Lymphoma Society ; National Cancer Institute (NCI) |
Link: | |
Quelle: | A Phase 1, Single Arm, Single Center Pilot Study of Medi4736, an Anti-Pdl1 Therapy, for Patients With Myelofibrosis |
Medientyp: | report |
Sonstiges: |
|